Rx Safety Communication In Face Of Uncertainty, Multiple Risks, To Be Examined By FDA Panel
This article was originally published in The Pink Sheet Daily
FDA’s Risk Communication Advisory Committee will delve into research on communicating uncertainty and how individuals perceive risk and seek information when confronted with multiple risks, during a June 29 meeting.
You may also be interested in...
FDA looking for more help from advisory committee on how much information about uncertainty to give as well as how best to communicate it to minority, uneducated groups.
FDA announces the October meeting unusually early following legislative efforts to further restrict access to the opioid pain reliever due to abuse worries.
FDA's Risk Communication Advisory Committee likes the concept of a standardized format in drug promotional labeling and print advertising, but remains concerned that different risk levels for different populations could negate its utility.